Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRINZOLAMIDE vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Open-angle glaucoma,Ocular hypertension
Mild to moderate pain,Fever
1 drop of 1% solution in the affected eye(s) twice daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily metabolized via hepatic cytochrome P450 isoenzymes, including CYP3A4, CYP2A6, CYP2C8, and CYP2C9, to its major metabolite N-desethylbrinzolamide.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~60% bound to plasma proteins (primarily albumin, also carbonic anhydrase in RBCs)
Approximately 10-20% bound to serum albumin; extensive tissue binding.
0.13–0.25 L/kg (confined primarily to plasma and RBCs; low Vd due to high tissue binding)
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Ophthalmic: systemic bioavailability ~10% (via corneal absorption); oral: not clinically used
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-60 m L/min, use with caution; no specific dose adjustment recommended but monitor for metabolic acidosis.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No specific adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Safety and efficacy not established in pediatric patients (no approved dosing).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific dose adjustment required; use with caution due to increased risk of corneal edema and metabolic acidosis in elderly patients.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Sulfonamide allergy: can cause serious adverse reactions similar to systemic sulfonamides, including Stevens-Johnson syndrome and toxic epidermal necrolysis.,Corneal endothelial function: use with caution in patients with compromised corneas due to potential for edema.,Bacterial keratitis: risk from contaminated ophthalmic solutions.,Ocular effects: may cause blurred vision, eye discomfort, and other local reactions.,Systemic effects: possible metabolic acidosis, especially in patients with renal impairment or concurrent oral carbonic anhydrase inhibitors.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to brinzolamide or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min) or hyperchloremic acidosis due to risk of metabolic acidosis,Concomitant use with oral carbonic anhydrase inhibitors (additive systemic effects)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No direct food interactions. However, brinzolamide may cause metabolic acidosis, so avoid carbonic anhydrase inhibitors (e.g., acetazolamide) and limit sodium bicarbonate intake. No specific dietary restrictions.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Brinzolamide is a carbonic anhydrase inhibitor. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenic effects unknown; second and third trimesters: possible fetal acidosis due to maternal carbonic anhydrase inhibition.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excretion in human milk unknown; M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug. Consider alternative therapy.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No pharmacokinetic studies in pregnancy; no dose adjustment recommended. Consider that pregnancy-induced physiologic changes (increased Vd, renal clearance) may reduce drug exposure; monitor clinical response.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Brinzolamide is a carbonic anhydrase inhibitor used topically for ocular hypertension. It reduces intraocular pressure by decreasing aqueous humor secretion. Unlike systemic CAIs, it causes fewer systemic side effects but may still cause metabolic acidosis in susceptible patients. Avoid use in patients with sulfonamide allergy due to cross-sensitivity. Monitor corneal endothelial function in patients with compromised corneas. Shake suspension well before use.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Shake the bottle well before each use.,Instill one drop in the affected eye(s) three times daily.,Wash hands before and after administration.,Remove contact lenses before instilling and wait 15 minutes before reinserting.,Do not touch the dropper tip to any surface.,Report any signs of allergy or severe eye discomfort.,May cause temporary blurred vision; avoid driving until clear.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Brinzolamide, a carbonic anhydrase inhibitor used for glaucoma, can reduce intraocular pressure and may cause systemic acidosis. Ketoconazole, an azole antifungal, inhibits CYP3A4 and can increase the systemic exposure of drugs metabolized by this enzyme. Although brinzolamide is primarily eliminated renally, co-administration may lead to additive metabolic acidosis, potentially enhancing ketoconazole's toxicity due to altered pH-dependent drug distribution and clearance."
"Olsalazine, a prodrug of mesalamine used for ulcerative colitis, can cause metabolic acidosis via carbonic anhydrase inhibition in the kidney. Brinzolamide, a topical carbonic anhydrase inhibitor for glaucoma, may additively reduce renal bicarbonate reabsorption, increasing the risk of hyperchloremic metabolic acidosis and electrolyte disturbances. Concurrent use may exacerbate acidosis, leading to symptoms like tachypnea, fatigue, and confusion."
"The combination of two carbonic anhydrase inhibitors, Brinzolamide (ophthalmic) and Diclofenamide (systemic), can lead to additive inhibition of carbonic anhydrase in renal tubules, resulting in enhanced systemic absorption and elevated plasma concentrations of Brinzolamide. This may cause severe metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and increased risk of sulfonamide-related adverse effects such as Stevens-Johnson syndrome. Patients may present with confusion, tachypnea, cardiac arrhythmias, or acute kidney injury."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRINZOLAMIDE vs ACEPHEN, answered by our medical review team.
BRINZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRINZOLAMIDE and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRINZOLAMIDE is: 1 drop of 1% solution in the affected eye(s) twice daily.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRINZOLAMIDE and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRINZOLAMIDE is classified as Category A/B. Brinzolamide is a carbonic anhydrase inhibitor. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded. Avoid in pregnancy . ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.